Abstract

The present invention relates to a recombinant chimeric protein containing immunogenic regions from the trans-sialidase (TS) protein and amastigote surface protein-2 (ASP-2) from Trypanosoma cruzi and a composition containing said protein that displayed vaccine potential in a murine model. The invention also comprises the use of the chimeric protein for manufacturing vaccines.

IPC Classes  ?

• C07K 14/44 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from protozoa
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 33/02 - Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis

Abstract

The present invention relates to a method for determining the presence or absence of the 4 serotypes of Dengue virus and differentiating the I and II lineages of Dengue virus serotype 2 in a biological sample. The present invention also relates to a method for detecting the 4 serotypes of DENV. The present invention also relates to the use of two pairs of primers or SNPs to determine the presence or absence of the 4 serotypes of DENV or to differentiate the strains of serotype 2 of the Dengue virus in a biological sample. The present invention also relates to a kit for detecting the 4 serotypes of dengue virus or for distinguishing between two strains of DENV-2.

IPC Classes  ?

• C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
• C12Q 1/686 - Polymerase chain reaction [PCR]
• C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

The present invention is related to the recombinant production of proteins by using a synthetic gene for high protein expression in Pichia pastoris. More specifically, the invention describes the production of Sm14 Schistosoma mansoni recombinant protein, where a synthetic gene was created to promote high expression of such protein, a gene which was cloned under control of two types of Pichia pastoris promoters: methanol-inducible promoter (AOXI) and constituent promoter (GAP). With these constructions, Pichia pastoris strains were genetically manipulated to efficiently produce vaccine antigen Sm14. The processes to produce and purify this protein from P. pastoris cells, which can be escalated for their industrial production, were also improved.

IPC Classes  ?

• C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C12N 15/81 - Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts

Abstract

Present invention provides monoclonal antibody against chitin oligomer through hybridoma technique. Antibodies abovementioned can be used as tools to fungal infection diagnostic and treatment. Pharmaceutical compositions and fungal infection treatment kits are also disclosed, including antibodies abovementioned. Moreover, fungal infection diagnostic method is also disclosed, using antibodies abovementioned and their use in drug preparation to treat fungal infections.

IPC Classes  ?

• C07K 16/14 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from fungi, algae or lichens

Abstract

The present invention provides a method for diagnosis, more specifically a method for the diagnosis of leishmaniasis based on multiplex LAMP assays. Furthermore, the invention provides a kit for diagnosis in a biological sample and oligonucleotides for use in said method.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• C12Q 1/6893 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for protozoa
• C12Q 1/6844 - Nucleic acid amplification reactions
• C12Q 1/6876 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
• C12Q 1/6888 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms

Abstract

The present invention describes capsule compositions consisting of crosslinked chitosan, beta-glucan or alginate, and encapsulates an environmentally compatible insecticide, especially larvicidal agents such as essential oils or essential oil components or other ingestible larvicides such as Bacillus thuringiensis which are lethal to the larvae and adults of pest insects, especially mosquito larvae.

IPC Classes  ?

• A01N 63/32 - Yeast
• A01N 25/10 - Macromolecular compounds
• A01N 25/26 - Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of applicationSubstances for reducing the noxious effect of the active ingredients to organisms other than pests in coated particulate form
• A01N 63/23 - B. thuringiensis
• A01P 7/04 - Insecticides

Abstract

The present invention relates to a protein of the scFv type in which said protein comprises a first polypeptide chain and a second polypeptide chain joined by a ligand, having the formula as follows: (VH domain)-(ligand)-(VL domain). The present invention further relates to a polynucleotide comprising the nucleotide sequence shown in SEQ ID NO: 1; to a vector comprising the polynucleotide as defined above; to the host cell comprising the vector as previously defined; and the composition comprising the aforementioned protein and a pharmaceutically acceptable excipient. The present invention further relates to a method for treating a disease or condition that results directly or indirectly from α4β1 integrin activity. The present invention further relates to an in vitro method for prognosing multiple sclerosis. The present invention further relates to the use of the previously defined protein or composition in the manufacture of a drug for the treatment of multiple sclerosis.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The present invention describes capsule compositions consisting of crosslinked chitosan, beta-glucan or alginate, and encapsulates an environmentally compatible ingestible larvicide, especially larvicidal agents such as essential oils or other ingestible larvicides such as Bacillus thuringiensis which are lethal to the larvae of pest insects, especially mosquito larvae.

IPC Classes  ?

• A01N 25/10 - Macromolecular compounds
• A01N 63/23 - B. thuringiensis
• A01N 65/36 - Rutaceae [Rue family], e.g. lime, orange, lemon, corktree or pricklyash
• A01N 65/22 - Lamiaceae or Labiatae [Mint family], e.g. thyme, rosemary, skullcap, selfheal, lavender, perilla, pennyroyal, peppermint or spearmint
• A01N 65/24 - Lauraceae [Laurel family], e.g. laurel, avocado, sassafras, cinnamon or camphor
• A01N 65/10 - Apiaceae or Umbelliferae [Carrot family], e.g. parsley, caraway, dill, lovage, fennel or snakebed
• A01N 65/26 - Meliaceae [Chinaberry or Mahogany family], e.g. mahogany, langsat or neem

Abstract

The drugs available for the treatment of cutaneous leishmaniasis have unsatisfactory efficacy, frequent and serious adverse effects, and require long treatment regimens. Thus, the search for new treatment alternatives for cutaneous leishmaniasis is considered a priority by the World Health Organization. Parenteral administration of pentavalent antimonials for the treatment of all forms of leishmaniasis, including cutaneous leishmaniasis, has several limitations. The therapy is long, requires repeated doses, and adverse reactions are frequent. Topical treatment is an attractive alternative for cutaneous leishmaniasis, offering significant advantages over systemic therapy: fewer adverse effects, ease of administration, and lower costs. The present inventors aimed to provide a fixed-dose topical composition containing at least one antileishmanial compound, providing adequate absorption of the active ingredient. Another objective of the present invention is to provide a topical, fixed-dose formulation containing a combination of antileishmanial compounds that has sufficient efficacy and safety to be used in the treatment of cutaneous leishmaniasis.

IPC Classes  ?

• A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
• A61K 9/107 - Emulsions
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 33/02 - Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
• A61K 31/29 - Antimony or bismuth compounds

Abstract

Provided herein are antileishmanial compounds, compositions comprising the antileishmanial compounds, and use thereof.

IPC Classes  ?

• A61K 31/4162 - 1,2-Diazoles condensed with heterocyclic ring systems
• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
• A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61P 33/02 - Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis

Abstract

The present invention relates to a method for screening potentially neuroprotective pharmaceuticals or substances. The present invention further relates to a kit for screening potentially neuroprotective pharmaceuticals or substances.

IPC Classes  ?

• C12N 5/079 - Neural cells
• C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
• C12Q 1/6813 - Hybridisation assays
• C12Q 1/6844 - Nucleic acid amplification reactions

Abstract

The present invention relates to a protein receptacle capable of receiving several exogenous polyamino acid sequences, concomitantly, for expression in various systems and for different uses. The present invention relates to polynucleotides capable of generating the aforementioned protein receptacle. The present invention also relates to vector and expression cassette comprising the aforementioned polynucleotide. The present invention further relates to the cell comprising the aforementioned expression vector or cassette. The present invention further relates to a method for producing said protein receptacle and for pathogen identification or disease diagnosis in vitro. The present invention further relates to the use of said protein receptacle and kit comprising said protein receptacle for diagnostic purposes or as vaccine compositions.

IPC Classes  ?

• C07K 1/04 - General processes for the preparation of peptides on carriers
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

The present invention provides a LAMP assay device that promotes isothermal RNA/DNA amplification applied to pathogen identification, comprising: a LAMP assay chamber (1); an electronics cabinet (4), a power supply means (7); and a top lid (2) for closing the LAMP assay chamber (1), wherein internally the device comprises: a metal cylindrical thermoblock (8) comprising openings (80) for positioning microtubes (81); a control board with central processing (14); a power electronics board (13); at least one heating element (10) in contact with the thermoblock (8) and adapted to heat the thermoblock (8) by induction; a temperature sensor (9) adapted to measure the temperature of the thermoblock (8); a plurality of RGB LEDs (12) positioned below the thermoblock (8) and adapted to excite each microtube positioned in the thermoblock (8); and a camera (11) positioned below the thermoblock (8) and adapted to capture images of each of the microtubes (81) positioned in the thermoblock (8). In addition, the invention provides a method for pathogen identification from a LAMP assay device.

IPC Classes  ?

• C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
• B01L 7/00 - Heating or cooling apparatusHeat insulating devices
• C12Q 1/6844 - Nucleic acid amplification reactions

Abstract

The present invention relates to a nucleic acid construct, a recombinant multiply-defective influenza virus, that promotes expression of an immunomodulatory protein in a host. This is applicable to the development of vaccines against infectious diseases, particularly those caused by influenza virus and Coronavirus.

IPC Classes  ?

• C12N 9/24 - Hydrolases (3.) acting on glycosyl compounds (3.2)
• A61K 39/145 - Orthomyxoviridae, e.g. influenza virus
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
• A61P 31/04 - Antibacterial agents
• A61K 39/09 - Streptococcus
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
• C07K 14/54 - Interleukins [IL]
• C12N 15/52 - Genes encoding for enzymes or proenzymes
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof

Abstract

The present invention pertains to the fields of pharmacology and medicine and relates to the use of coumarin derivative compounds for the treatment of asthma and/or chronic obstructive pulmonary disease (COPD). The inventors identified that inhaled braylin has high therapeutic efficacy in the treatment of asthma and COPD, with efficacy comparable to systemic dexamethasone, and represents an unprecedented alternative to conventional treatments.

IPC Classes  ?

• A61K 31/37 - Coumarins, e.g. psoralen
• A61P 11/06 - Antiasthmatics

Abstract

An immunogenic composition comprising: a) one or more Plasmodium-derived ribosomal or ribosomal associated protein or immunogenic fragment thereof which has a sequence which is at least about 80%, 85%, 90%, 95%, 98%, 99% or 100% identical to a ribosomal or ribosomal associated protein or an immunogenic fragment of a ribosomal or ribosomal associated protein recited in FIG. 1; or a ribosomal or ribosomal associated protein or peptide or immunogenic fragment thereof as recited in FIG. 2 or FIG. 3; and/or b) a polynucleotide encoding one or more protein, peptide or immunogenic fragment of a); wherein the immunogenic composition is for use in eliciting an immune response in a subject to treat or prevent malaria. Also provided are Plasmodium-derived ETRAMPs and/or histones, or immunogenic fragments thereof, for use in eliciting an immune response in a subject, preferably to treat or prevent malaria.

IPC Classes  ?

• A61K 39/015 - Hemosporidia antigens, e.g. Plasmodium antigens
• A61P 33/06 - Antimalarials
• C12N 15/861 - Adenoviral vectors

Abstract

The present invention relates to nucleic acid aptamers comprising a nucleotide sequence having the following general formula (1), or a pharmaceutically acceptable salt thereof: TAGGGAAGAGAAGGACATATGAT-X1-TTGACTAGTACATGACCAC TTGA (formula 1), in which X1 is the nucleotide sequence as defined in any of the sequences of SEQ ID Nos: 1-10, SEQ ID Nos: 21-30 and SEQ ID Nos: 41-50, or a sequence with at least 90% identity with the same and an equivalent function to the corresponding sequences. The present invention further relates to a composition comprising at least one aptamer as previously defined. The present invention further relates to the use of an aptamer or composition as previously defined for producing a medicinal drug for the treatment of cancer. The present invention further relates to a diagnostic kit comprising the aptamers or composition as previously defined. The present invention further relates to a method for detecting or diagnosing a tumour, comprising bringing at least one aptamer or composition as previously defined into contact with a cell, tissue or specimen from an individual, and detecting the bond between the aptamer and the cell, tissue or specimen. The present invention further relates to a method for treating cancer, comprising a step which consists in administering to an individual a therapeutically effective amount of an aptamer or composition as previously defined.

IPC Classes  ?

• C12N 15/115 - Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith
• A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to substitute guinea pig rat models for craniotomy training. In this scenario, the present invention provides a rat model for training in medical craniotomy techniques comprising a body (2) with four legs (21) and a tail (22), and a head (1), similar to those of a rat, wherein the body (2) and the head (1) are attachable (3), and wherein the head (1) comprises a rigid skull. (1), similar to those of a rat, wherein the body (2) and the head (1) are attachable (3), and wherein the head (1) comprises a rigid skull.

IPC Classes  ?

• G09B 23/34 - Anatomical models with removable parts
• G09B 23/36 - Models for scientific, medical, or mathematical purposes, e.g. full-sized device for demonstration purposes for zoology
• B33Y 80/00 - Products made by additive manufacturing

Abstract

The present invention relates to a veterinary vaccine composition based on fatty-acid-binding proteins (FABP) from parasites. Specifically, the invention discloses a veterinary vaccine composition based on the Schistosoma mansoni protein (rSm14) or homologous proteins of Fasciola hepatica (FhFABPs) that provide a homogeneous, long-term immune response against parasitic worms. The invention is also intended to provide a method for treating and preventing infection caused by parasitic worms, in particular Fasciola hepatica, and also the use of these proteins in a vaccine composition against parasitic worms.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61P 33/10 - Anthelmintics
• C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof

Abstract

Fasciola hepaticaFasciola hepatica, and also the use of these proteins in a vaccine composition against parasitic worms.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61P 33/10 - Anthelmintics

Abstract

The present invention relates to an in vitro method for the differential diagnosis of infections of the central nervous system by herpesvirus, comprising the steps of DNA extraction from a sample of human cerebrospinal fluid; multiplex real-time PCR amplification using the primers as defined in any one of the sequences of SEQ ID NOs: 1 to 12; and identification of the amplicon(s) produced based on the melting temperature (Tm) from high-resolution melting (HRM) curves. The present invention also relates to a kit for the differential diagnosis of infections of the central nervous system by herpesvirus, comprising a combination of primers selected from the group of SEQ ID NOs: 1 to 12; commercial human DNA and water as negative controls; and plasmid DNA containing the viral sequences as positive controls; and reagents for the multiplex real-time PCR reaction. The present invention also relates to the use of a combination of primers selected from the group of SEQ ID NOs: 1 to 12, for the differential diagnosis of infections of the central nervous system by herpesvirus.

IPC Classes  ?

• C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
• C12Q 1/686 - Polymerase chain reaction [PCR]
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof

Abstract

The present invention relates to a recombinant chimeric protein containing immunogenic regions from the trans-sialidase (TS) protein and amastigote surface protein-2 (ASP-2) from Trypanosoma cruzi and a composition containing said protein that displayed vaccine potential in a murine model. The invention also comprises the use of the chimeric protein for manufacturing vaccines.

IPC Classes  ?

• C07K 14/44 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from protozoa
• A61K 39/005 - Trypanosoma antigens
• A61P 33/02 - Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis

Abstract

The present invention relates to the diagnosis of COVID-19. Within this context, the present invention provides an RNA extraction cassette comprising: a base (1) and a bottom lid (2), the extraction cassette comprising, between the base (1) and the bottom lid (2), at least one layer composed of an absorbent porous/fibrous matrix (6) intended for obtaining the viral RNA for amplification using the RT-LAMP technique; and a filter paper layer (4), the extraction cassette comprising a locking system between the base (1) and the bottom lid (2), the locking system being designed to keep the layer composed of a porous/fibrous matrix and the filter paper layer (4) compressed between the base (1) and the bottom lid (2), the base (1) comprising a central opening (14) directly above the filter paper layer (4) and peripheral openings (15). In addition, the invention also provides a method of diagnosis in a biological sample obtained using said RNA extraction cassette and a kit for diagnosis in a biological sample comprising same.

IPC Classes  ?

• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
• C12Q 1/6844 - Nucleic acid amplification reactions
• C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage

Abstract

Despite recent efforts to eradicate malaria worldwide, this parasitic disease is still considered a major public health problem, with a total of 219 million malaria cases and 435,000 deaths in 2017 After a decade of use, however, resistance to CQ has emerged in some locations, including Southeast Asia, South America, and the Western Pacific region, spreading progressively into malaria-endemic areas, including Africa, where increases in malaria mortality have been observed. This has led, in recent years, to the adoption of artemisinin-based combination therapies. Artemisinin-based combination therapies remain effective in most parts of the world, but recent cases of resistance in Southeast Asia call for new approaches and especially new drugs to treat malaria. Thus, the present invention features CQ analogues of Formula (I) that exhibited high activity against CQ-sensitive and CQ-resistant blood parasites and were also active in mice. The present invention also provides pharmaceutical compositions comprising the compounds of Formula (I), use of said compounds, and methods for treating conditions caused by blood parasites.

IPC Classes  ?

• C07D 215/46 - Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
• A61P 33/06 - Antimalarials

Abstract

The present invention relates to the field of diagnostic medicine, vaccinology and biotechnology. More specifically, the present invention relates to a chimeric protein for use in diagnosing visceral leishmaniasis in humans and dogs, including individuals coinfected with the human immunodeficiency virus (HIV) and a vaccine containing said chimeric protein for prophylactic or therapeutic use.

IPC Classes  ?

• C07K 19/00 - Hybrid peptides
• A61K 39/008 - Leishmania antigens
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• A61P 33/02 - Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis

Abstract

The present invention provides a method of diagnosis, more specifically a method of diagnosis of Leishmaniasis based on LAMP assays. Furthermore, the invention provides a kit for diagnosis in a biological sample and oligonucleotides for use in said method.

IPC Classes  ?

• C12Q 1/6893 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for protozoa
• C12Q 1/6844 - Nucleic acid amplification reactions

Abstract

The drugs available for treating cutaneous leishmaniasis have unsatisfactory effectiveness, frequent and serious side effects, and require long treatment plans. The search for novel treatment options for cutaneous leishmaniasis is therefore considered to be a priority by the World Health Organisation. The parenteral administration of pentavalent antimonials for treating all forms of leishmaniasis, including cutaneous leishmaniasis, has several limitations. Treatment takes a long time, requiring repeat doses, and side effects are frequent. Topical treatment is an attractive option for cutaneous leishmaniasis, offering significant advantages over systemic therapy: fewer side effects, easy administration, and lower costs. The aim of the present inventors was to provide a topical fixed-dose composition containing at least one antileishmanial compound and providing suitable absorption of the active principle. Another aim of the present invention is to provide a topical fixed-dose formulation that contains a combination of antileishmanial compounds and is sufficiently effective and safe for use in treating cutaneous leishmaniasis.

IPC Classes  ?

• A61K 9/107 - Emulsions
• A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
• A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A61K 33/24 - Heavy metalsCompounds thereof
• A61P 33/02 - Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis

Abstract

The drugs available for treating cutaneous leishmaniasis have unsatisfactory effectiveness, frequent and serious side effects, and require long treatment plans. The search for novel treatment options for cutaneous leishmaniasis is therefore considered to be a priority by the World Health Organisation. The parenteral administration of pentavalent antimonials for treating all forms of leishmaniasis, including cutaneous leishmaniasis, has several limitations. Treatment takes a long time, requiring repeat doses, and side effects are frequent. Topical treatment is an attractive option for cutaneous leishmaniasis, offering significant advantages over systemic therapy: fewer side effects, easy administration, and lower costs. The aim of the present inventors was to provide a topical fixed-dose composition containing at least one antileishmanial compound and providing suitable absorption of the active principle. Another aim of the present invention is to provide a topical fixed-dose formulation that contains a combination of antileishmanial compounds and is sufficiently effective and safe for use in treating cutaneous leishmaniasis.

IPC Classes  ?

• A61K 9/107 - Emulsions
• A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
• A61K 33/24 - Heavy metalsCompounds thereof
• A61P 33/02 - Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis

Abstract

The present invention relates to chimeric proteins, their uses and production method comprising native protein fractions from Leishmania infantum for the Visceral Leishmaniasis diagnosis. The invention also relates to nucleic acid, expression cassette, expression vector, host cell, visceral leishmaniasis diagnostic kit, visceral leishmaniasis diagnostic kit, visceral leishmaniasis diagnostic method, and vaccine composition.

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• C07K 14/44 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from protozoa
• A61K 39/008 - Leishmania antigens
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression

Abstract

The invention describes the therapeutic use of the compound 3,3',4,4',5,5'-hexamethoxylobelanine for treating leishmaniasis. Pharmaceutical compositions comprising 3,3',4,4',5,5'-hexamethoxylobelanine and use thereof are also contemplated.

IPC Classes  ?

• C07D 211/32 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
• A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
• A61P 33/02 - Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis

Abstract

The present invention generally relates to pharmaceutical formulations comprising, as active ingredient, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) and at least one pharmaceutically acceptable excipient. The invention further provides a method for producing said formulation, a drug, a method for treating leishmaniasis and the use of the formulation. The formulations of the invention constitute an innovative therapeutic alternative in controlling leishmaniasis.

IPC Classes  ?

• A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
• A61K 9/51 - Nanocapsules
• A61P 33/02 - Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis

Abstract

The present invention relates to an scFv protein, in which said protein includes a first chain of polypeptides and a second chain of polypeptides joined by a binder, having the following formula: (VH domain) – (binder) – (VL domain). The present invention also relates to a polynucleotide comprising the nucleotide sequence shown in SEQ ID NO: 1; to a vector including the polynucleotide as defined previously; to the host cell including the vector as defined previously; and to the composition including the aforementioned protein and a pharmaceutically acceptable excipient. The present invention also relates to a method for treating an illness or condition resulting directly or indirectly from the activity of the integrin α4β1. The present invention also relates to an in-vitro method for predicting multiple sclerosis. The present invention also relates to the use of the protein or of the composition defined previously in the manufacture of a drug for treating multiple sclerosis.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
• C12N 15/13 - Immunoglobulins
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• G01N 33/563 - ImmunoassayBiospecific binding assayMaterials therefor involving antibody fragments
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

The present invention relates to an scFv protein, in which said protein includes a first chain of polypeptides and a second chain of polypeptides joined by a binder, having the following formula: (VH domain) ? (binder) ? (VL domain). The present invention also relates to a polynucleotide comprising the nucleotide sequence shown in SEQ ID NO: 1; to a vector including the polynucleotide as defined previously; to the host cell including the vector as defined previously; and to the composition including the aforementioned protein and a pharmaceutically acceptable excipient. The present invention also relates to a method for treating an illness or condition resulting directly or indirectly from the activity of the integrin ?4?1. The present invention also relates to an in-vitro method for predicting multiple sclerosis. The present invention also relates to the use of the protein or of the composition defined previously in the manufacture of a drug for treating multiple sclerosis.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

The present invention relates to a LAMP testing device using isothermal amplification of RNA/DNA to identify pathogens, comprising: a LAMP testing chamber (1); an electronics cabinet (4), power supply means (7); and a top cover (2) for closing the LAMP testing chamber (1), the device containing: a cylindrical metal dry block (8) with apertures (80) used to position microtubes (81); a control panel with central processing (14); an electronic power board (13); at least one heating element (10) which is in contact with the dry block (8) and is designed to heat the dry block (8) by induction; a temperature sensor (9) designed to measure the temperature of the dry block (8); a plurality of RGB LEDs (12) that are positioned beneath the dry block (8) and are designed to excite each microtube positioned inside the dry block (8); and a chamber (11) that is positioned beneath the dry block (8) and designed to capture images of each of the microtubes (81) positioned in the dry block (8). The invention also relates to a method for identifying pathogens using a LAMP testing device.

IPC Classes  ?

• C12Q 1/6844 - Nucleic acid amplification reactions
• G01N 21/64 - FluorescencePhosphorescence
• B01L 7/00 - Heating or cooling apparatusHeat insulating devices

Abstract

The present invention relates to a nucleic acid construct and a recombinant influenza virus unable to multiply for inducing the expression of an immunomodulatory protein in a host and being of use in the development of vaccines against infectious diseases, particularly those caused by the influenza virus and coronavirus.

IPC Classes  ?

• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
• C12N 15/24 - Interleukins
• C12N 7/01 - Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material
• A61K 39/145 - Orthomyxoviridae, e.g. influenza virus
• C07K 14/54 - Interleukins [IL]
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
• A61P 31/04 - Antibacterial agents

Abstract

The present invention relates to a nucleic acid construct, a recombinant multiply-defective influenza virus, that promotes expression of an immunomodulatory protein in a host. This is applicable to the development of vaccines against infectious diseases, particularly those caused by influenza virus and Coronavirus.

IPC Classes  ?

• A61K 39/145 - Orthomyxoviridae, e.g. influenza virus
• A61P 31/04 - Antibacterial agents
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
• C07K 14/54 - Interleukins [IL]
• C12N 7/01 - Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material
• C12N 15/24 - Interleukins
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Abstract

The present invention relates to a method for the diagnosis or prognosis of HTLV-1 and/or HTLV-2 infections, involving: (1) collecting samples of serum from patients; (2) preparing MT-2 and MoT cells for cell fixation and permeabilization and subsequently marking MT-2 and MoT cells; (3) mixing serums from human individuals with the preparation of MT-2 and MoT cells, with subsequent incubation of the mixture and washing; (4) adding SAPE and biotinylated anti-IgG1 antibody, with subsequent incubation of the mixture and washing; (5) subjecting the samples to flow cytometry; (6) analyzing the reactivity profile of anti-HTLV-1/2 IgG1 antibodies; and (7) using a synchronous or asynchronous algorithm to determine whether or not there is an HTLV-1 and/or HTLV-2 infection. The present invention also relates to a kit for diagnosing HTLV-1 and/or HTLV-2 infections using flow cytometry, said kit comprising fixed and marked lymphocytic cells in suspension, which are infected by HTLV-1 (MT-2) and HTLV-2 (MoT); a reagent containing biotinylated human anti-IgG1 antibodies; a serum sample from uninfected human individuals as a negative control; a serum sample from human individuals infected with HTLV-1 and/or HTLV-2 as a positive control; and a developing reagent.

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
• C12R 1/91 - Cell lines
• C12R 1/93 - Animal viruses

Abstract

The present invention provides monoclonal antibodies against chitin oligomer using the hybridoma technique. Said antibodies can be used as tools for diagnosing and treating fungal infections. Pharmaceutical compositions and kits for treating fungal infections including said antibodies are also disclosed. A method for diagnosing fungal infections using said antibodies and the use thereof in the preparation of a drug for treating fungal infections are also disclosed.

IPC Classes  ?

• C07K 16/14 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from fungi, algae or lichens
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 31/4196 - 1,2,4-Triazoles
• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• G01N 33/577 - ImmunoassayBiospecific binding assayMaterials therefor involving monoclonal antibodies
• A61P 31/10 - Antimycotics

Abstract

The present invention relates to substitute models for laboratory rats used in craniotomy training. In this context, the present invention provides a rat biomodel for training in medical craniotomy techniques, comprising a body (2) with four legs (21), a tail (22) and a head (1), similar to those of a rat, in which the body (2) and the head (1) can be fitted together (3) and in which the head (1) includes a rigid skull.

IPC Classes  ?

• G09B 23/28 - Models for scientific, medical, or mathematical purposes, e.g. full-sized device for demonstration purposes for medicine
• G09B 23/34 - Anatomical models with removable parts
• G09B 23/36 - Models for scientific, medical, or mathematical purposes, e.g. full-sized device for demonstration purposes for zoology
• B29C 64/00 - Additive manufacturing, i.e. manufacturing of three-dimensional [3D] objects by additive deposition, additive agglomeration or additive layering, e.g. by 3D printing, stereolithography or selective laser sintering
• B33Y 10/00 - Processes of additive manufacturing

Abstract

The present invention provides a LAMP assay device comprising a heating chamber (5) adapted to receive a support rail (2) of at least one sample, in which the support rail (2) is inserted into it through a sample insertion opening (1), in addition, the heating chamber (5) comprises: at least one internal heating element (8a, 8b); a circuit of light-emitting elements (6) positioned on a front or rear wall; and a light sensor circuit (7) on a wall opposite the light emitting element circuit (6).

IPC Classes  ?

• G01N 21/78 - Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator producing a change of colour
• C12Q 1/6844 - Nucleic acid amplification reactions
• B01L 7/00 - Heating or cooling apparatusHeat insulating devices

Abstract

The present invention refers to polypeptides with asparaginase activity that have an increased rate of self-processing compared to human wild L-asparaginase (ASRGLI), resulting from a mutation in the ASRGLI glycine rich loop called HGG loop (Histidine 8-Glycine 9-Glycine 10). Polynucleotides that encode the polypeptides of invention are also described herein. Expression cassettes comprising said polynucleotides, expression vectors, host cells, pharmaceutical compositions, uses of the invention polypeptide in the manufacture of a preventive medicine or cancer treatment and methods to produce the polypeptide of invention and to prevent or treat cancer are also described.

IPC Classes  ?

• A61K 38/50 - Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
• A61P 35/02 - Antineoplastic agents specific for leukemia
• C12N 15/66 - General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligationUse of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease

Abstract

Despite recent efforts to eradicate malaria worldwide, this parasitic disease is still considered to be a major public health issue, with a total of 219 million cases of malaria and 435,000 deaths in 2017. However, after a decade of use, resistance to CQ has emerged in some areas, including Southeast Asia, South America and the Western Pacific Region, spreading gradually through areas where malaria is endemic, including Africa, where increased mortality from malaria has been observed. This has led to the adoption of combined artemisinin-based therapies in recent years. Combined artemisinin-based therapies remain effective in most parts of the world, but recent cases of resistance in Southeast Asia require new approaches and in particular new drugs to treat malaria. Accordingly, the present invention discloses CQ analogs of formula (I) that exhibit high levels of activity against blood parasites that are sensitive and resistant to CQ and were also active in mice. The present invention also provides pharmaceutical compositions including the compounds of formula (I), the use of said compounds and methods for treating conditions caused by blood parasites.

IPC Classes  ?

• A61K 31/47 - QuinolinesIsoquinolines
• A61K 31/4706 - 4-Aminoquinolines8-Aminoquinolines, e.g. chloroquine, primaquine
• A61P 33/06 - Antimalarials

Abstract

The present invention relates to a protein receptacle into which various exogenous polyamino acid sequences can be inserted simultaneously for expression in various systems and for various uses. The present invention relates to polynucleotides which can generate the previously mentioned protein receptacle. The present invention also relates to a vector and expression cassette comprising the previously mentioned polynucleotide. The present invention also relates to a cell comprising the previously mentioned vector or expression cassette. The present invention also relates to a method for producing said protein receptacle and identifying pathogens or diagnosing diseases in vitro. The present invention also relates to the use of said protein receptacle and kit comprising said protein receptacle for diagnosis or as vaccine compositions.

IPC Classes  ?

• C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• C07K 19/00 - Hybrid peptides
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 39/005 - Trypanosoma antigens
• A61K 39/10 - BrucellaBordetella, e.g. Bordetella pertussis
• A61K 39/12 - Viral antigens
• A61K 39/35 - Allergens
• A61K 39/205 - Rhabdoviridae, e.g. rabies virus
• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• C12N 15/12 - Genes encoding animal proteins
• C12N 15/62 - DNA sequences coding for fusion proteins
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• G01N 33/566 - ImmunoassayBiospecific binding assayMaterials therefor using specific carrier or receptor proteins as ligand binding reagent
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

A multiplexed lateral flow assay device includes an impermeable internal reservoir having an opening to receive a sample deposition. A fluid distributor pad is arranged in fluid communication with a lower surface of the internal reservoir and divides a portion of the sample deposition substantially equally among a plurality of flow paths. Lateral flow assays having a plurality of flow lines are aligned with flow paths of the distributor pad. An impermeable paper top cover has a first window arranged over the opening of the internal reservoir, and at least a second window arranged over the test results of the lateral flow assays. A housing element houses the reservoir, the distributor pad and lateral flow assays. The housing element includes an impermeable bottom cover and a spacer element arranged between the top and bottom covers and, provides a gap between the lateral flow assays and the impermeable paper top cover.

IPC Classes  ?

• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• G01N 33/536 - ImmunoassayBiospecific binding assayMaterials therefor with immune complex formed in liquid phase

Abstract

A multiplexed lateral flow device includes an impermeable internal reservoir having an opening to receive a sample deposition. A fluid distributor pad is arranged in fluid communication with a lower surface of the internal reservoir. The fluid distributor pad includes a paper based microfluidic element having a pattern of a hydrophobic material to distribute a portion of the sample deposition substantially equally among a plurality of flow paths. Lateral flow assays having a plurality of flow lines are aligned with flow paths of the distributor pad. An impermeable top cover has a first window arranged over the opening of the internal reservoir, and at least a second window arranged over the test results of the lateral flow assays. A housing element houses the reservoir, the distributor pad and lateral flow assays. The housing element includes an impermeable bottom cover and a spacer element arranged between the top and bottom covers and, provides a gap between the lateral flow assays and the impermeable top cover.

IPC Classes  ?

• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
• G01N 33/571 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses for venereal disease, e.g. syphilis, gonorrhoea, herpes

Abstract

visceral leishmaniasisvisceral leishmaniasis. The invention also relates to the nucleic acid, expression cassette, expression vector, host cell, composition for the diagnosis of visceral leishmaniasis, kit for the diagnosis of visceral leishmaniasis, method of diagnosis of visceral leishmaniasis and vaccine composition.

IPC Classes  ?

• C07K 14/44 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from protozoa
• C12N 15/62 - DNA sequences coding for fusion proteins
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• A61K 39/008 - Leishmania antigens
• C12N 1/00 - Microorganisms, e.g. protozoaCompositions thereofProcesses of propagating, maintaining or preserving microorganisms or compositions thereofProcesses of preparing or isolating a composition containing a microorganismCulture media therefor
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

E. coliE. coli L-asparaginase that has been modified to reduce interaction thereof with amino acids other than asparagine, most preferably glutamine. Polynucleotides encoding the polypeptides of the invention, expression cassettes comprising said polynucleotides, expression vectors, host cells, pharmaceutical compositions, uses of the polypeptide of the invention in manufacturing a medication for preventing or treating cancer, and methods for producing the polypeptide of the invention and for preventing or treating neoplasms are also described herein.

IPC Classes  ?

• C12N 9/82 - Asparaginase
• A61K 38/50 - Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
• C12N 15/55 - Hydrolases (3)
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• A61P 35/02 - Antineoplastic agents specific for leukemia

Abstract

The present invention relates to a method for diagnosing rubella using recombinant proteins. The recombinant proteins developed can be used individually or together, are of high purity and have high capacity for discriminating the rubella virus. The invention also enables the development of a second-generation subunit vaccine. In general, the invention relates to a recombinant protein, a synthetic DNA sequence, an expression vector, a host cell, a composition, a kit for diagnosing rubella, the use of at least one recombinant protein and methods for producing a recombinant protein and diagnosing rubella.

IPC Classes  ?

• C07K 14/19 - Rubella virus
• A61K 39/20 - Rubella virus
• C12N 15/40 - Proteins from RNA viruses, e.g. flaviviruses
• C12N 15/62 - DNA sequences coding for fusion proteins
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

The present invention relates to polypeptides that have immunogenic activity, which can be used alone or together, having high discriminatory capacity for screening the hepatitis C virus (HCV). The polypeptides according to the invention comprise at least two antigenic HCV regions selected from the nucleocapsid region and nonstructural regions NS3, NS4 and NS5. The invention also relates to the nucleic acid, expression cassette, expression vector, host cell, method for producing the polypeptides, composition, use of the polypeptides, kit for immunological screening for HCV and/or for diagnosing hepatitis C, and also to the methods for immunological screening for HCV and for diagnosing hepatitis C.

IPC Classes  ?

• C07K 14/18 - Togaviridae, e.g. flavivirus, pestivirus, yellow fever virus, hepatitis C virus, japanese encephalitis virus
• C07K 19/00 - Hybrid peptides
• C07K 17/00 - Carrier-bound or immobilised peptidesPreparation thereof
• A61K 39/29 - Hepatitis virus
• C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
• C12N 15/51 - Hepatitis viruses
• C12N 15/62 - DNA sequences coding for fusion proteins
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• G01N 33/576 - ImmunoassayBiospecific binding assayMaterials therefor for hepatitis

Abstract

Visceral leishmaniasis is one of the most neglected diseases in the world and attacks humans and other mammals. Dogs are the main domestic link of visceral leishmaniasis as they are considered to be the main source of infection for vectors. Sick animals with or without clinical manifestation (asymptomatic) need to be correctly diagnosed. The invention provides methods and kits for detecting canine visceral leishmaniasis with a high level of sensitivity and specificity, including in seemingly healthy animals that do not present any clinical manifestations, using isolated lipophosphogylcans of L. infantum. The method according to the invention has a sensitivity of 91.7%, a specificity of 98.5%, and an accuracy of 99.7%, and can adequately discriminate between serums of dogs that are sick and infected and those that are infested with parasites and clinically healthy, and with a low rate of cross-reactivity during testing of samples of dogs infected with other infectious agents.

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• A61K 39/008 - Leishmania antigens

Abstract

A heterologous expression cassette, DNA construct and vaccine composition for immunization against flavivirus and/or other pathogens. DNA constructs, recombinant viruses and vaccine compositions containing the recombinant viruses were obtained. This invention also concerns and provide an improved expression vector of the live-attenuated yellow fever 17D virus. Modifications in the expression cassette of heterologous proteins in the intergenic E/NS1 region of the yellow fever 17D vaccine virus, were made. The two new functional domains inserted in the expression cassette were (1) a coding sequence for the N-glycosylation motif, located between the NS1 N-terminal motif and the heterologous protein and (2) a sequence which promoted the proteolytic cleavage, or not, of the recombinant protein in such a way as to release it from its C-terminal containing the transmembrane domains and, consequently, from its association with the membrane of the endoplasmatic reticulum—ER.

IPC Classes  ?

• C07K 14/18 - Togaviridae, e.g. flavivirus, pestivirus, yellow fever virus, hepatitis C virus, japanese encephalitis virus
• A61K 39/12 - Viral antigens
• C12N 15/66 - General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligationUse of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
• C12N 15/86 - Viral vectors
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present invention provides a real-time PCR method which allows, in a single step, simultaneous detection of causative agents of bacterial meningitis, more specifically, Neisseria meningitidis, Streptococcus pneumoniae and Haemophilus influenzae. To this end, primers were developed that are used to amplify particular regions of the genomes of said bacteria. The presence of the bacteria in a sample is indicated by the presence of the amplicon, which is detected by detection methods that are suitable for the PCR method used.

IPC Classes  ?

• C12Q 1/6876 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
• C12Q 1/686 - Polymerase chain reaction [PCR]
• C12R 1/21 - Haemophilus
• C12R 1/36 - Neisseria
• C12R 1/46 - Streptococcus

Abstract

The present invention provides a LAMP assay device comprising a heating chamber (5) designed to receive a holding rack (2) for at least one sample, the holding rack (2) being inserted therein by means of a sample insertion opening (1), the heating chamber (5) also comprising: at least one internal heating element (8a,8b); a light-emitting element circuit (6) located on a front wall or back wall; and a light sensor circuit (7) in a wall opposite to the light-emitting element circuit (6).

IPC Classes  ?

• B01L 7/00 - Heating or cooling apparatusHeat insulating devices
• C12Q 1/6844 - Nucleic acid amplification reactions
• C12M 1/38 - Temperature-responsive control
• G01N 21/78 - Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator producing a change of colour

Abstract

The present invention relates to polypeptides with asparaginase activity, which have an increased self-processing rate in comparison to wild-type human L-asparaginase (ASRGL1), said polypeptides having a mutation in the glycine-rich loop of ASRGL1, denominated the HGG (Histidine 8-Glycine 9-Glycine 10) loop. Polynucleotides encoding the polypeptides of the invention, expression cassettes comprising said polynucleotides, expression vectors, host cells, pharmaceutical compositions, uses of the polypeptide of the invention in manufacturing a medication for preventing or treating cancer, and methods for producing the polypeptide of the invention and for preventing or treating cancer are also described herein.

IPC Classes  ?

• A61K 38/50 - Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
• A61P 35/00 - Antineoplastic agents
• A61P 35/02 - Antineoplastic agents specific for leukemia
• C12N 9/82 - Asparaginase
• C12N 15/55 - Hydrolases (3)
• C12N 15/66 - General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligationUse of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease

Abstract

The present invention relates to polypeptides with asparaginase activity, which have an increased self-processing rate in comparison to wild-type human L-asparaginase (ASRGL1), said polypeptides having a mutation in the glycine-rich loop of ASRGL1, denominated the HGG (Histidine 8-Glycine 9-Glycine 10) loop. Polynucleotides encoding the polypeptides of the invention, expression cassettes comprising said polynucleotides, expression vectors, host cells, pharmaceutical compositions, uses of the polypeptide of the invention in manufacturing a medication for preventing or treating cancer, and methods for producing the polypeptide of the invention and for preventing or treating cancer are also described herein.

IPC Classes  ?

• C12N 9/82 - Asparaginase
• A61K 38/50 - Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
• C12N 15/55 - Hydrolases (3)
• C12N 15/66 - General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligationUse of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
• A61P 35/00 - Antineoplastic agents
• A61P 35/02 - Antineoplastic agents specific for leukemia

Abstract

The instant invention relates to a qualitative predictive method, to a method, use and kit applied to the early differential diagnosis of the most prevalent forms of bacterial and viral meningitis, enabling to detect and distinguish the different forms of meningitis. The invention uses a qualitative predictive method based on combined detection and sequential analysis of the presence/absence of at least three out of four specific biomarkers.

IPC Classes  ?

• A61K 49/00 - Preparations for testing in vivo
• A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
• A61K 39/095 - Neisseria
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• G01N 33/92 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving lipids, e.g. cholesterol

Abstract

2 is selected from one of the following radicals: zidovudine, amprenavir or an acyclic phosphonate chain, as shown below. This invention also relates to the use and treatment method using the Formulae I, II and III compounds. According to this invention, these compounds are also used for the treatment of infections caused by HBV or co-infection caused by HIV and HBV.

IPC Classes  ?

• C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
• A61P 31/18 - Antivirals for RNA viruses for HIV
• C07F 9/6558 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system

Abstract

The present invention provides a multifunctional device for containing, transporting, storing and collecting biological samples from small animals, comprising a base (1), a top wall (2), a front wall (3), a rear wall (4), a first side wall (5) and a second side wall (5), in which all the walls (2, 3, 4, 5) have a plurality of orifices, in which the base (1) and the top wall (2) are connected to the side (5), front (3) and rear (4) walls by means of fastening elements or form a single component by means of moulding, and the side walls (5) are connected to the front (3) and rear (4) walls by means of fastening elements or form a single component by means of moulding, and in which the top wall (2) comprises at least one access door (20) that allows access to the interior of the device, said door having a plurality of orifices.

IPC Classes  ?

• A01K 1/02 - PigstiesDog-kennelsRabbit-hutches or the like
• A01K 1/03 - Housing for domestic or laboratory animals
• B65D 85/50 - Containers, packaging elements or packages, specially adapted for particular articles or materials for living organisms, articles or materials sensitive to changes of environment or atmospheric conditions, e.g. land animals, birds, fish, water plants, non-aquatic plants, flower bulbs, cut flowers or foliage

Abstract

The present invention provides a real-time multiplex RT-qPCR method which allows, in a single step, simultaneous detection of the Oropouche virus (OROV), Oropouche-like virus and/or Mayaro virus. To this end, primers were developed that are used to amplify particular regions of the genomes of the viruses. The presence of the viruses in a sample is indicated by the formation of fluorescence released by the specific probes for each virus.

IPC Classes  ?

• C12Q 1/6888 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
• C12Q 1/686 - Polymerase chain reaction [PCR]

Abstract

The present invention provides a lateral flow diagnostic device with radial symmetry comprising a base (B) and a lid (T), which comprises at least one sample input opening (1) and at least two observation windows (2), and the base (B) comprises at least one sample acquisition element (3) and at least two test-strip beds (5), wherein each observation opening (2) in the lid (T) corresponds to one or more beds (5), and in each bed (5) one or more test strips (4) can be positioned, said at least one sample acquisition element (3) being in communication with the at least two test strips (4). The invention also provides a system for reading a lateral flow diagnostic device with radial symmetry comprising the following modules: image acquisition optical module (13), illumination module, processing and control module (15), and storage module, wherein the image and acquisition optical module (13) is adapted to acquire an image of a lateral flow diagnostic device with radial symmetry, and the processing and control module (15) is adapted to manage and extract information from the system.

IPC Classes  ?

• G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
• G01N 21/84 - Systems specially adapted for particular applications
• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers

Abstract

The present patent application discloses recombinant or synthetic T. gondii antigens that can be used for diagnosing acute and chronic toxoplasmosis. Combinations for detecting IgG anti-T. gondii antibodies and IgM anti-T. gondii antibodies are disclosed, comprising the antigens GRA7, ROP1, p35 and GRA6, or fragments thereof. In addition, the present patent application discloses nucleotide sequences encoding the antigens of the present invention, as well as systems for recombinant expression and systems for purification of said antigens. Furthermore, stabilized compositions comprising the antigens of the invention are also provided, as well as said antigens coupled to microbeads.

IPC Classes  ?

• C07K 14/45 - Toxoplasma
• C12N 15/30 - Genes encoding protozoal proteins, e.g. from Plasmodium, Trypanosoma, Eimeria
• A61K 39/002 - Protozoa antigens
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• C07K 17/08 - Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer

Abstract

The present invention relates to methods for identifying and validating gene products from the Cryptococcus fungus as effective targets for therapeutic drug screening. The use of five genes identified in Cryptococcus, responsible for the production of nucleolar protein 16 (NOP16), a scramblase, otubain-1, beta DNA-polymerase and a hypothetical protein, proved to be useful for studying metabolic pathways for the growth, proliferation and survival of C. neoformans or C. gattii, for pigmentation, as well as the production of cellular or extracellular subproducts that are important for the pathogenicity and virulence of the microrganism. Cryptococcus wild-type strains or strains that suffered mutation for the interruption of genes were used to screen compounds with antifungal activity.

IPC Classes  ?

• C12Q 1/18 - Testing for antimicrobial activity of a material
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• C12N 1/14 - Fungi Culture media therefor
• C12N 1/15 - Fungi Culture media therefor modified by introduction of foreign genetic material
• C12N 15/09 - Recombinant DNA-technology
• C12R 1/645 - Fungi

Abstract

The present invention relates, in general, to a combination of Crotamine and drugs used for therapy. More specifically, the present invention relates to a combination of Crotamine, a toxin from the snake Crotalus durissus terrificus, and drugs used in conventional anti-leishmaniasis therapy. The present invention also provides a pharmaceutical composition, a medicament, a method for treating leishmaniasis and use of the composition. Said toxin acts as a nanopeptide that interacts with human DNA and penetrates cells, delivering drugs, specifically Amphotericin B, Pentamidine or Glucantime®, inside infected macrophages, for the purpose of improving pharmacological efficiency, as well as reducing the side effects and adverse effects of said drugs in treating leishmaniases, particularly American Tegumentary Leishmaniasis, specifically caused by the species L. amazonensis, responsible for the diffuse cutaneous form of the disease.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A61K 31/155 - Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (HN=C(OH)NH2), isothiourea (HN=C(SH)—NH2)
• A61K 31/29 - Antimony or bismuth compounds
• A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
• A61K 31/685 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
• A61P 33/02 - Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis

Abstract

The present invention pertains to the field of the production of recombinant proteins, using a synthetic gene for increased expression of the protein in Pichia pastoris. More specifically, the invention describes the production of the recombinant Sm14 protein of Schistosoma mansoni, with the creation of a synthetic gene for increased expression of this protein, which gene was cloned under the control of two types of Pichia pastoris promoters: methanol-induced promoter (AOX1) and constitutive promoter (GAP). Strains of Pichia pastoris were genetically engineered with these constructs to produce the Sm14 vaccine antigen efficiently. Improved methods are also provided for producing and purifying this protein from P. pastoris cells, which can be scaled for industrial production.

IPC Classes  ?

• A61K 39/002 - Protozoa antigens
• A61P 33/12 - Schistosomicides
• C07K 14/44 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from protozoa
• C12N 15/12 - Genes encoding animal proteins
• C12N 15/67 - General methods for enhancing the expression
• C12N 15/81 - Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

Streptococcus pneumoniae designated serotype 6C, and assays and monoclonal antibodies useful in identifying same. Also disclosed is a novel pneumococcal polysaccharide with the repeating unit {→2) glucose 1 (1→3) glucose 2 (1→3) rhamnose (1→3) ribitol (5→phosphate}. This new serotype may be included in pneumococcal vaccines.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• A61K 31/715 - Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkagesDerivatives thereof, e.g. ethers, esters
• A61K 39/09 - Streptococcus
• C07K 16/12 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from bacteria
• C08B 37/00 - Preparation of polysaccharides not provided for in groups Derivatives thereof
• C12Q 1/14 - StreptococcusStaphylococcus
• C12R 1/46 - Streptococcus
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

The present invention describes a method for chemically and/or biologically activating the surface of originally inert polymer materials. Polymer surface activation occurs exclusively by means of the physical incorporation of at least one linear long-chain compound containing at least one reactive terminal group into the inert polymer, in the presence of at least one solvent.

IPC Classes  ?

• C08J 7/00 - Chemical treatment or coating of shaped articles made of macromolecular substances
• C08J 3/07 - Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media from polymer solutions
• C08J 3/12 - Powdering or granulating

Abstract

The present invention relates to a combination of the drugs curcumin (Cur), which is a natural polyphenol, and sodium diethyldithiocarbamate (DETC), or its precursor disulfiram (DS), which exhibits synergistically increased antimalarial activity.

IPC Classes  ?

• A61K 31/12 - Ketones
• A61K 31/145 - Amines, e.g. amantadine having sulfur atoms, e.g. thiurams (N—C(S)—S—C(S)—N or N—C(S)—S—S—C(S)—N)Sulfinylamines (—N=SO)Sulfonylamines (—N=SO2)
• A61P 33/06 - Antimalarials

Abstract

The present invention relates to DNA constructs, recombinant viruses and vaccine compositions containing the recombinant viruses obtained. This invention also concerns an improvement made to the expression vector of the live attenuated virus of yellow fever 17D. The present invention provides for the introduction of modifications to the expression cassette of heterologous proteins in the intergenic region E/NS1 of the vaccine virus of yellow fever 17D. The two new functional domains inserted into the expression cassette were (1) a coding sequence for N-glycosylation motif, located between the N-terminal NS1 motif and the heterologous protein and (2) a sequence that promotes the proteolytic cleavage or otherwise of the recombinant protein in order to release same from the C-terminal of same containing the transmembrane domains and, consequently, from the association thereof with the membrane of the endoplasmic reticulum RE.

IPC Classes  ?

• C12N 15/86 - Viral vectors
• C12N 15/40 - Proteins from RNA viruses, e.g. flaviviruses
• C12N 15/66 - General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligationUse of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
• A61K 39/12 - Viral antigens
• C12N 7/01 - Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material

Abstract

The present invention relates to a trap for collecting mosquitoes. More particularly, the present invention provides a trap for collecting anthropophilic mosquitoes of relevance for public health, such as Anopheles mosquitoes. The trap is a portable entomological research and surveillance tool and method which offer an alternative to the conventional method using human bait, known under the name of human landing catches (HLC). The trap according to the invention showed its greatest effectiveness for Anopheles marajoara, an important vector, besides protecting the collector from the risk of contracting malaria, since the collector remains inside an enclosure out of reach of the mosquitoes, making surveillance more comfortable and less troublesome, especially in the cases where long collection periods are necessary. In addition, the trap according to the invention makes it possible to obtain more reliable collection data since, the collector being entirely isolated from physical contact with the mosquitoes, the collector can collect for long periods.

IPC Classes  ?

• A01M 1/10 - Traps
• E04H 15/02 - Tents combined or specially associated with other devices

Abstract

The present invention relates to HIV-inhibiting compounds consisting of isatin derivatives of formulae I, II and III, as represented below (formulae I, II and III), wherein, in the formulae I, II and III, R1 is selected from H, CH3 or Cl, R2 is selected from one of the following radicals: zidovudine, amprenavir or an acyclic phosphonate chain, these compounds being represented below. The present invention also relates to the use and to the treatment method using the compounds of formulae I, II and III. The compounds according to the present invention are also used for the treatment of infection caused by HBV or co-infections caused by HIV and HBV.

IPC Classes  ?

• C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
• C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 209/34 - Oxygen atoms in position 2
• A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
• A61K 31/4192 - 1,2,3-Triazoles
• A61P 31/18 - Antivirals for RNA viruses for HIV
• A61P 31/12 - Antivirals

Abstract

The present invention relates to an apparatus designed for synchronising an electroencephalogram (EEG) recorded by any digital equipment with physical events (sensorial, visual or acoustic stimuli) and behavioural events (motor response, vocal response), in order to allow averaging the EEG signal for visualisation of evoked potentials or event-related potentials, which are an important subject of research in neurosciences and clinical investigation of neurological and psychiatric pathologies. The present invention allows transforming any digital EEG recorder into an apparatus for recording evoked potentials. The invention furthe rprovides a method for the analogous synchronisation of EEG with luminous events, oscillatory events of an electrical nature and motor behaviour events.

IPC Classes  ?

• A61B 5/0484 - Electroencephalography using evoked response
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/16 - Devices for psychotechnicsTesting reaction times
• G06F 19/00 - Digital computing or data processing equipment or methods, specially adapted for specific applications (specially adapted for specific functions G06F 17/00;data processing systems or methods specially adapted for administrative, commercial, financial, managerial, supervisory or forecasting purposes G06Q;healthcare informatics G16H)
• A61B 5/05 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves

Abstract

The present invention relates to the use of mefloquine against Mycobacterium tuberculosis. The present invention further contemplates the combination of mefloquine with pharmaceutical drugs used in first and second choice treatments of tuberculosis, achieving a shorter treatment period of tuberculosis (TB) and of multiresistant tuberculosis (MDR-TB).

IPC Classes  ?

• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61K 31/4409 - Non-condensed pyridinesHydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/133 - Amines, e.g. amantadine having hydroxy groups, e.g. sphingosine
• A61P 31/06 - Antibacterial agents for tuberculosis

Abstract

The instant invention relates to a qualitative predictive method, to a method, use and kit applied to the early differential diagnosis of the most prevalent forms of bacterial and viral meningitis, enabling to detect and distinguish the different forms of meningitis. The invention uses a qualitative predictive method based on combined detection and sequential analysis of the presence/absence of at least three out of four specific biomarkers.

IPC Classes  ?

• A61K 49/00 - Preparations for testing in vivo
• A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
• A61K 39/095 - Neisseria
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• G01N 33/92 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving lipids, e.g. cholesterol

Abstract

The present invention provides a perillic acid derivative in the form of a salt having formula II, with anti-cancer activity, in which the counter-ion M+ comprises alkali or alkaline earth metals, such as Na+ (sodium), K+ (potassium), Ca+2/2 (calcium), etc. The invention further relates to a method for producing the compound, a pharmaceutical composition, the use of the compound and a cancer treatment method.

IPC Classes  ?

• C07C 61/22 - Unsaturated compounds having a carboxyl group bound to a six-membered ring
• C12P 7/40 - Preparation of oxygen-containing organic compounds containing a carboxyl group
• A61K 31/185 - AcidsAnhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
• A61P 35/00 - Antineoplastic agents
• C07C 51/16 - Preparation of carboxylic acids or their salts, halides, or anhydrides by oxidation

Abstract

Fasciola hepatica. The process includes the steps of: (a) performing lysis of cells containing the fatty acid binding protein to obtain a lysate; (b) clarifying the lysate obtained in step (a) to obtain a clarified lysate; (c) loading the clarified lysate in a column containing an anion exchange resin; (d) eluting proteins from the column by pH changes in the column; and (e) separating contaminant proteins from the fatty acid binding protein by gel-filtration.

IPC Classes  ?

• C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• C07K 1/36 - ExtractionSeparationPurification by a combination of two or more processes of different types
• C12N 15/81 - Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
• C07K 14/395 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from fungi from yeasts from Saccharomyces
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present invention relates to new phenylaminopyrimidine (FAP)-derived compounds of general formulae I and II: wherein R1 in formula I is: X* in formula II is selected from one of the compounds below: Y in formula II is The compounds of the present invention are powerful, non-specific inhibitors of tyrosine kinase; the present invention also aims at the use of these compounds for the treatment of cancer patients, involving the inhibition of the enzyme tyrosine kinase.

IPC Classes  ?

• C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
• A61P 35/02 - Antineoplastic agents specific for leukemia

Abstract

The present invention relates to a differential diagnostic method using flow cytometry, performed by means of differential fluorescent marking of biological agents, such as cells and pathogens of interest, with fluorescent substances. The diagnostic method generally consists in performing fluorescent marking of biological agents with gradual concentrations of fluorescent substances, and in analyzing the reactivity profile of IgG1 to the biological agents. The present invention further relates to a diagnostic kit.

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• G01N 21/64 - FluorescencePhosphorescence

Abstract

ABSTRACTThe present invention relates to diphenyloxyalkylamine derivatives and aryloxyalkylamine derivatives that are structurally analogous to mexiletine, said derivatives having important biological activity and not causing the undesired side effects observed with the prototype, as well as with other drugs from the same therapeutic class as the prototype. The derivatives of the present invention have formulas II and III and are used for treating, preventing or inhibiting pulmonary inflammatory diseases, for example, asthma and chronic obstructive pulmonary disease (COPD).R1,N,R2R4R5 OR3R6 R8R7 Formula IIIDate Recue/Date Received 2020-11-24

IPC Classes  ?

• A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
• A61P 11/06 - Antiasthmatics
• A61P 11/08 - Bronchodilators
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• C07C 217/14 - Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring

Abstract

The present invention relates to diphenyloxyalkylamine derivatives and aryloxyalkylamine derivatives that are structurally analogous to mexiletine, said derivatives having important biological activity and not causing the undesired side effects observed with the prototype, as well as with other drugs from the same therapeutic class as the prototype. The derivatives of the present invention have formulas II and III and are used for treating, preventing or inhibiting pulmonary inflammatory diseases, for example, asthma and chronic obstructive pulmonary disease (COPD).

IPC Classes  ?

• C07C 217/14 - Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
• A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
• A61P 11/06 - Antiasthmatics
• A61P 11/08 - Bronchodilators
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

The present invention relates to a process for producing polymeric structures that have activated surfaces. The process proved to be simple, quick, with high production capacity and low operating costs. The process occurs by depositing a polymer solution, which is assisted by a high electric field, on a conductive liquid surface to produce particles and/or filaments that have an activated surface. More particularly, the process of the present invention has the ability to produce particles and/or filaments that have chemically activated surfaces, in a single process.

IPC Classes  ?

• D01D 7/00 - Collecting the newly-spun products
• D01D 5/00 - Formation of filaments, threads, or the like
• B29B 9/06 - Making granules by dividing preformed material in the form of filamentary material, e.g. combined with extrusion
• B29B 9/12 - Making granules characterised by structure or composition
• D01F 1/10 - Other agents for modifying properties
• D01F 6/16 - Monocomponent man-made filaments or the like of synthetic polymersManufacture thereof from homopolymers obtained by reactions only involving carbon-to-carbon unsaturated bonds from polymers of unsaturated carboxylic acids or unsaturated organic esters, e.g. polyacrylic esters, polyvinyl acetate
• D01F 6/22 - Monocomponent man-made filaments or the like of synthetic polymersManufacture thereof from homopolymers obtained by reactions only involving carbon-to-carbon unsaturated bonds from polymers of cyclic compounds with one carbon-to-carbon double bond in the side chain from polystyrene

Abstract

Lu. longipalpis polynucleotides are also disclosed. In one embodiment, a method is disclosed for inducing an immune response to sand fly saliva. In other embodiments, methods for treating, diagnosing, or preventing Leishmaniasis are disclosed.

IPC Classes  ?

• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
• C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• C07K 16/20 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
• A61K 38/00 - Medicinal preparations containing peptides

Abstract

The present invention relates to a differential diagnostic method using flow cytometry, performed by means of differential fluorescent marking of biological agents, such as cells and pathogens of interest, with fluorescent substances. The diagnostic method generally consists in performing fluorescent marking of biological agents with gradual concentrations of fluorescent substances, and in analysing the reactivity profile of IgG1 to the biological agents. The present invention further relates to a diagnostic kit.

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
• C12R 1/90 - Protozoa

Abstract

P. pastoris cells, which can be scaled for industrial production.

IPC Classes  ?

• C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• C12N 15/81 - Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present invention refers to the subsampler and to a subsampling method that allows for the execution of environmental monitoring without the use of large sample volumes, thus ensuring specimen wealth and expedited analyses.

IPC Classes  ?

• G01N 1/22 - Devices for withdrawing samples in the gaseous state
• G01N 1/10 - Devices for withdrawing samples in the liquid or fluent state
• G01N 1/12 - DippersDredgers
• G01N 1/18 - Devices for withdrawing samples in the liquid or fluent state with provision for splitting samples into portions
• G01N 33/18 - Water
• A01K 61/00 - Culture of aquatic animals

Abstract

The present invention relates to a process for producing polymeric structures that have activated surfaces. The process proved to be simple, quick, with high production capacity and low operating costs. The process occurs by depositing a polymer solution, which is assisted by a high electric field, on a conductive liquid surface to produce particles and/or filaments that have an activated surface. More particularly, the process of the present invention has the ability to produce particles and/or filaments that have chemically activated surfaces, in a single process.

IPC Classes  ?

• D01D 5/11 - Flash-spinning
• B29B 9/06 - Making granules by dividing preformed material in the form of filamentary material, e.g. combined with extrusion
• B29B 9/12 - Making granules characterised by structure or composition
• D01D 1/02 - Preparation of spinning solutions

Abstract

Enterococcus, and any other bacteria containing the PBP2-a protein or homologous sequences. The invention also relates to the use of the monoclonal antibodies capable of recognizing and binding to the PBP2-a protein and to other proteins having sequences homologous to PBP2-a in a complementary immunodiagnostic test for detecting resistance to beta-lactam antibiotics.

IPC Classes  ?

• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
• C07K 16/12 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from bacteria

Abstract

The present invention pertains to the field of production of recombinant proteins, using a synthetic gene for increased expression of the protein in Pichia pastoris. More specifically, the invention describes the production of a recombinant Sm14 protein of Schistosoma mansoni, by providing a synthetic gene for increased production of Sm14 protein, producing said gene and genetically manipulating the Pichia pastoris strain with said gene in order to produce a vaccine effectively. Improved methods are also provided for producing and purifying this protein from P. pastoris cells, which can be scaled for industrial production.

IPC Classes  ?

• C12N 15/12 - Genes encoding animal proteins
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12N 15/79 - Vectors or expression systems specially adapted for eukaryotic hosts
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 39/17 - Newcastle disease virus

Abstract

The present application aims at the performance of biomonitoring without requiring large sample volumes. Sampling in an aquatic environment is performed using an equipment comprising a tray provided with a tap and housing a perforated tray partitioned into 24 parts by a partitioning element. The equipment is positioned at the surface so as to allow the substrate to enter inside the tray, undesirable material is removed and excess water is drained before anesthetics are added and the contents are partitioned by the partitioning element. To end the process, the anesthetic solution is drained, and the substrates in the quadrats are collected and conditioned. The equipment may be optionally provided with legs.

IPC Classes  ?

• A01M 23/02 - Collecting-traps

Abstract

A device particularly suitable for feeding premature newborns consists of a cup with a raised colored graded scale placed on the cup side for easy visualization, a flow reducer composed of folds, a round spout formed from the cup rim facilitating contact with the mouth of the baby, and a lid of the cup rim which fits using pressure to avoid food contamination.

IPC Classes  ?

• A47G 19/22 - Drinking vessels or saucers used for table service

Abstract

The present invention relates to vaccines of DNA that code for specific viral sequences. The DNA vaccines against yellow fever according to the invention are based on the sequence that codes for the yellow fever virus envelope protein (p/YFE). Besides the wild p/YFE construct, sequence E was also fused with the sequence that codes for the human lysosome-associated membrane protein (h-LAMP), generating the construct (pL/YFE). The results of the invention are considered to be very promising, since both constructs can induce T-cell response against the same epitopes induced by the 17DD vaccine, and the pL/YFE construct can also induce a satisfactory concentration of neutralising antibodies. The pL/YFE vector was inoculated in mice, before intracerebral challenge with the virus of yellow fever. Surprisingly, 100% of the mice immunised with pL/YFE survived the challenge.

IPC Classes  ?

• C12N 15/40 - Proteins from RNA viruses, e.g. flaviviruses
• C12N 15/12 - Genes encoding animal proteins
• A61K 39/12 - Viral antigens

Abstract

The present invention relates to a method for inducing an immune response to the dengue virus, on the basis of DNA and 17D chimeric virus vaccines in combined or co-administered immunisation. The scope of the present invention also includes DNA vaccines against the four serotypes of the dengue virus, produced by forming, from each viral serotype of the dengue virus (DENV1-4), various recombinant plasmids that contain the gene that codes for the E protein, or that contain only the sequence that corresponds to the domain III of this protein. The invention also provides a vaccine composition consisting of (a) DNA vaccines against the four serotypes of the dengue virus; (b) chimeric viruses comprising the modified yellow fever vaccination virus 17D; and (c) a pharmaceutically acceptable carrier, all of which are covered by the scope of the invention.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• C12N 7/01 - Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material
• C12N 15/40 - Proteins from RNA viruses, e.g. flaviviruses
• C12N 15/86 - Viral vectors
• A61P 31/14 - Antivirals for RNA viruses

Abstract

T. gondii parasite.

IPC Classes  ?

• A61K 39/012 - Coccidia antigens
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present invention relates to monoclonal antibodies capable of recognising and binding to the PBP2-a protein and to other proteins having sequences homologous to PBP2-a, including pathogenic species such as the methyciline-resistant Staphylococcus Aureus (MRSA), coagulase-negative Staphilococcus, Staphylococcus sciuri and Enterococcus, and any other bacteria containing the PBP2-a protein or homologous sequences. The invention also relates to the use of the monoclonal antibodies capable of recognising and binding to the PBP2-a protein and to other proteins having sequences homologous to PBP2-a in a complementary immunodiagnostic test for detecting resistance to beta-lactam antibiotics.

IPC Classes  ?

• A61K 39/40 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum bacterial
• C07K 16/12 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from bacteria
• C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes

Abstract

The present invention relates to monoclonal antibodies capable of recognising and binding to the PBP2-a protein and to other proteins having sequences homologous to PBP2-a, including pathogenic species such as the methyciline-resistant Staphylococcus Aureus (MRSA), coagulase-negative Staphilococcus, Staphylococcus sciuri and Enterococcus, and any other bacteria containing the PBP2-a protein or homologous sequences. The invention also relates to the use of the monoclonal antibodies capable of recognising and binding to the PBP2-a protein and to other proteins having sequences homologous to PBP2-a in a complementary immunodiagnostic test for detecting resistance to beta-lactam antibiotics.

IPC Classes  ?

• C07K 16/12 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from bacteria
• C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
• A61K 39/40 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum bacterial

Abstract

The present patent application relates to an apparatus with rotating links for environmental enrichment and based on the presentation of a physical stimulus (locomotion). The apparatus is manufactured with a 12'' PVC tube (3 rings 20 cm wide), 22'' stainless steel (3 strips measuring 6x100cm), metal (cast iron) chains of 80cm for supporting the apparatus and making it of easier access from the floor (in the case of nursing animals), and two metallic devices (snap hooks) made of plated wire that allow the PVC rings to rotate independently. The apparatus comprises rotating links and a swivel-like, twisting element arranged between the rotating links to enable the animals to turn the links in opposite directions, or even to keep them stationary while another animal is playing on the link above or below.

IPC Classes  ?

• A01K 1/00 - Housing animalsEquipment therefor
• A01K 15/02 - Training or exercising equipment, e.g. mazes or labyrinths for animals

Abstract

The present invention relates to the use of different recombinant antigens obtained from Leishmania chagasi or Leishmania infantum genes in assays for identifying, detecting and quantifying specific antibodies in biological material, including serum, plasma, saliva and urine from human beings, dogs and other Leishmania vertebrate hosts. These recombinant antigens, or genes or parts of genes that encode same, can be used for diagnosing leishmaniases, both the infection and/or disease. The present invention further relates to the use of these recombinant antigens, or genes or parts of genes that encode same, or formulations containing these antigens, for the treatment and/or immunisation of human beings, dogs and other vertebrate hosts, against leishmaniases.

IPC Classes  ?

• C07K 14/44 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from protozoa
• C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
• C07K 16/20 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
• A61K 39/008 - Leishmania antigens
• C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The present invention relates to a recombinant BCG vaccine strain of Mycobacterium bovis that expresses the Sm14 antigen of Schistosoma mansoni (BCGr Pasteur ΔLeuD/pΔK410-hsp60*-Sm14). The vaccine strain according to the present invention is used for combating infection by parasites, particularly Schistosoma mansoni. The vaccine strain is a leucine-auxotrophic strain derived from the BCG substrain Pasteur, supplemented for leucine after genetic transformation with the construct pΔK410-hsp60*-SM14. The effectiveness of the BCGr Pasteur ΔLeuD/pΔK410-hsp60*-Sm14 strain for combating Schistosoma mansoni infection by expressing the recombinant Sm14 antigen in vivo is demonstrated in the present invention.

IPC Classes  ?

• C12N 15/76 - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for ActinomycesVectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Streptomyces
• A61P 33/10 - Anthelmintics
• A61P 31/06 - Antibacterial agents for tuberculosis
• A61P 35/00 - Antineoplastic agents

Abstract

A system for creation of perspective images of the present invention includes: A new method for transforming three-dimensional (3D) world coordinates into two-dimensional (2D) screen coordinates using a negative exponential algorithm, instead of the classical projection algorithms that have the distance ‘z’ to the observer in the denominator (division algorithms); A new method for generating realistic perspective images of objects located at any distance from the observer (positive, negative or zero distances) that does not need any correction for zero or negative distances; The demonstration of practical use of the invention by computer graphics programs that generates and displays perspective images based on this exponential algorithm.

IPC Classes  ?

• G06T 15/20 - Perspective computation

Abstract

The present utility model application relates to an easy-to-use object suitable for feeding premature newborns in an alternative manner, useful for phonation therapy and enabling feeding by different persons. The device basically consists of a cup with a coloured graduated scale embossed on the wall of the cup for easy viewing, a flow reducer comprising corrugations, a rounded spout formed by the edge of the cup for ease of contact with the infant's mouth, and a lid that is pressure-fitted onto the cup's edge to prevent contamination of the food contained in the cup.

IPC Classes  ?

• A61J 9/00 - Feeding-bottles in general

Abstract

The present invention concerns to recombinant influenza viruses and modified Vaccinia Ankara viruses (MVA), and to a process for construction of recombinant influenza viruses and modified vaccinia Ankara viruses (MVA) with genes that encode for the T.gondii parasite SAGI (MVA) and SAG2 (MVA and influenza) proteins, by means of a homologous recombination technique between two transfer vectors (for construction of MVA virus) and reverse genetics (for construction of influenza virus). Additionally, the present invention describes a vaccine composition using recombinant influenza viruses and modified vaccinia Ankara viruses (MVA), or recombinant adenoviruses and modified vaccinia Ankara viruses (MVA), for immunization against infections caused by the T. gondii parasite.

IPC Classes  ?

• A61K 39/002 - Protozoa antigens
• C12N 15/30 - Genes encoding protozoal proteins, e.g. from Plasmodium, Trypanosoma, Eimeria